Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Iovance Biotherapeutics, Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06566092CT.gov Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rhabdomyosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ln-144 (this asset) | Iovance Biotherapeutics, Inc. | P1 | C · 39 |
| Ipilimumab | Children's National Research Institute | P2 | BB |
| Calcium Phosphate | Children's Oncology Group | P3 | BB |
| Irinotecan | Milton S. Hershey Medical Center | P2 | BB |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
| Adriamycin | Children's National Research Institute | P2 | B |
| Vincristine Sulfate | Children's Oncology Group | P3 | B |
| Vinorelbine Ditartrate | Children's Oncology Group | P3 | B |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | B |
+42 more in the Rhabdomyosarcoma cohort
Other indications for ln-144
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Central Nervous System Lymphoma | — | P1 | CC · 43 |
| Soft Tissue Sarcoma | — | P1 | CC · 41 |
| Ewing Sarcoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ln-144 in Rhabdomyosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ln-144-rhabdomyosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →